13F Holdings
中文EN

SDGR Schrodinger, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1490978 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY4.8%
TTM net income YoY66.3%
TTM EPS YoY67.1%
Revenue 3-yr CAGR10.5%
Net income 3-yr CAGR—

Margins

Gross margin58.5%
Operating margin-49.6%
Net margin-22.0%
FCF margin-43.4%
EBITDA margin-47.5%

Returns

ROE-19.0%
ROA-9.4%
ROIC (approx.)-108.6%
Asset turnover0.43x

Leverage & solvency

Liabilities / assets50.7%
Debt / equity0.00x
Current ratio2.75x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.90x
Accruals ratio8.4%
Payout ratio—
Capex / revenue1.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$255.87M$207.54M$216.67M$180.96M$137.93M
Cost of revenue$113.25M$75.46M$75.97M$79.93M$72.31M
Gross profit$142.61M$132.08M$140.69M$101.02M$65.62M
R&D expense$173.14M$201.78M$181.77M$126.37M$90.90M
SG&A expense$95.41M$99.68M$99.15M$90.83M$64.01M
Operating income-$166.90M-$209.30M-$177.45M-$146.82M-$111.44M
Pretax income-$102.33M-$185.71M$42.92M-$149.12M-$100.81M
Income tax$939,000$1.41M$2.20M$63,000$411,000
Net income-$103.27M-$187.12M$40.72M-$149.19M-$100.39M
EBITDA-$160.87M-$203.14M-$171.90M-$142.47M-$108.60M
EPS (basic)-1.41-2.570.57-2.10-1.42
EPS (diluted)-1.41-2.570.54-2.10-1.42
Weighted avg. shares (diluted)73.44M72.67M74.99M71.17M70.59M
Balance sheet
Cash & equivalents$230.52M$162.66M$161.07M$95.72M$123.27M
Short-term investments$164.95M$204.80M$307.69M$360.61M$456.21M
Receivables$83.04M$235.69M$65.99M$55.95M$31.74M
Current assets$519.26M$634.99M$567.80M$533.99M$625.06M
PP&E, net$19.46M$24.20M$23.32M$14.24M$10.03M
Goodwill$4.79M$4.79M$4.79M$4.79M$0
Intangibles——$0$587,000$0
Total assets$726.16M$823.23M$802.96M$688.59M$756.49M
Current liabilities$189.14M$191.75M$133.67M$108.80M$91.21M
Total liabilities$362.11M$401.78M$254.40M$240.68M$199.40M
Shareholders' equity$364.05M$421.44M$548.56M$447.89M$557.07M
Shares outstanding——62.98M62.16M61.83M
Cash flow statement
Operating cash flow$13.90M-$157.37M-$136.73M-$119.68M-$70.67M
Capital expenditure$1.44M$7.31M$13.40M$8.01M$7.17M
Free cash flow$12.46M-$164.68M-$150.14M-$127.70M-$77.84M
Investing cash flow$57.90M$148.84M$193.03M$90.02M-$16.81M
Financing cash flow$2.93M$10.12M$9.05M$2.11M$7.95M
Depreciation & amortization$6.02M$6.16M$5.55M$4.34M$2.85M
Stock-based compensation$43.00M$49.90M$47.84M$39.63M$26.49M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.